Superworth

ALX Oncology EPS ALXO

Diluted earnings per share by quarter and over the last twelve months, from 2019.

Last 12 months, to Jun 30, 2026
−$1.13
Latest quarter, Q2 FY26
−$0.13
Fiscal year 2025
−$1.90

ALX Oncology's earnings per share was −$1.13 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.13.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$1.90n/a
FY2024−$2.59n/a
FY2023−$3.75n/a
FY2022−$3.03n/a
FY2021−$2.06n/a
FY2020−$7.64n/a
FY2019−$7.55n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.13n/a−$1.13
Q1 FY26−$0.17n/a−$1.49
Q4 FY25−$0.42n/a−$1.90
Q3 FY25−$0.41n/a−$2.02
Q2 FY25−$0.49n/a−$2.19
Q1 FY25−$0.58n/a−$2.46
Q4 FY24−$0.54n/a−$2.59
Q3 FY24−$0.58n/a−$2.98
Q2 FY24−$0.76n/a−$3.64
Q1 FY24−$0.71n/a−$3.72
Q4 FY23−$0.93n/a−$3.75
Q3 FY23−$1.24n/a−$3.57

Against its peers

Companies in Drug Manufacturers - General nearest ALX Oncology's size, closest first, today.

CompanyEPS, 12 monthsGrowth
ALXOALX Oncology−$1.13
NATRNatures Sunshine Products$1.01+36% a year
LFVNLifevantage$0.40−46% a year
SPROSpero Therapeutics$0.11
ARVNArvinas$0.16
ATNMActinium Pharmaceuticals$0.36
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
COLLCollegium Pharmaceutical$1.24+19% a year
Peer median$0.65

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on ALX Oncology

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.